Canada markets close in 4 hours 17 minutes

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.2800-0.1000 (-2.96%)
As of 11:05AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close3.3800
Open3.3050
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.2800 - 3.3050
52 Week Range2.2200 - 5.0500
Volume2,569
Avg. Volume40,890
Market Cap175.875M
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-2.5900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

    Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registration Docum

  • Insider Monkey

    Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript

    Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript March 28, 2024 Inventiva S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Inventiva Annual Results 2023 conference call. At this […]

  • GlobeNewswire

    Inventiva announces the nomination of Andre Turenne as Director

    Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directo